VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $40,429,128 | +2.1% | 793,036 | 0.0% | 16.12% | +23.5% |
| Q2 2023 | $39,604,218 | +52.5% | 793,036 | +14.4% | 13.06% | +22.1% |
| Q1 2023 | $25,975,102 | -21.8% | 693,039 | 0.0% | 10.70% | -26.0% |
| Q4 2022 | $33,231,220 | +78.4% | 693,039 | -10.7% | 14.45% | +112.3% |
| Q3 2022 | $18,625,000 | +2.9% | 776,039 | -6.7% | 6.81% | -25.4% |
| Q2 2022 | $18,108,000 | -32.5% | 832,166 | -25.1% | 9.12% | -28.2% |
| Q1 2022 | $26,842,000 | +1.5% | 1,111,485 | 0.0% | 12.70% | +14.9% |
| Q4 2021 | $26,442,000 | -25.8% | 1,111,485 | -20.9% | 11.06% | -12.3% |
| Q3 2021 | $35,656,000 | +12.7% | 1,405,421 | 0.0% | 12.60% | +1.1% |
| Q2 2021 | $31,636,000 | +14.0% | 1,405,421 | 0.0% | 12.47% | +40.0% |
| Q1 2021 | $27,757,000 | -53.0% | 1,405,421 | -36.8% | 8.90% | -54.3% |
| Q4 2020 | $59,064,000 | – | 2,222,970 | – | 19.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $110,721,000 | 37.88% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $50,150,000 | 29.14% |
| Pivotal bioVenture Partners Investment Advisor LLC | 2,222,970 | $59,064,000 | 19.47% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $61,365,000 | 4.73% |
| TPG Group Holdings (SBS) Advisors, Inc. | 4,941,213 | $131,288,000 | 1.46% |
| RA Capital Management | 3,710,699 | $98,593,000 | 1.38% |
| Foresite Capital Management IV, LLC | 465,821 | $12,377,000 | 1.34% |
| Opaleye Management Inc. | 335,200 | $8,906,000 | 1.16% |
| Novo Holdings A/S | 416,937 | $11,078,000 | 0.48% |
| Affinity Asset Advisors, LLC | 30,000 | $797,000 | 0.42% |